Current Drug Treatment News and Events | Page 25

Current Drug Treatment News and Events, Drug Treatment News Articles.
Sort By: Most Relevant | Most Viewed
Page 25 of 25 | 1000 Results
Novel class of antibiotics shows promise against plague, drug-resistant bacteria
Pathogenic bacteria are rapidly developing resistance to the arsenal of microbial therapies -- and driving researchers to identify families of therapeutics with new modes of action. This week in mBio, an international group of scientists report on laboratory experiments suggesting that a novel LpxC inhibitor can treat multi-drug resistant bacterial infections, including many that originate in hospitals. (2017-07-25)

Immune cells the missing ingredient in new bladder cancer treatment
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer. (2017-07-24)

Shortcut method in drug development
A research group at Uppsala University presents in PNAS a new, small-scale method that may become a smart shortcut for determining the 'bioavailability' of a pharmaceutical drug within cells. 'Finding out how a therapeutic drug affects the body means having to consider many different factors that can influence the cells' internal environment. Our method may be a way of substantially facilitating this stage.' (2017-07-12)

Effective protection against hip fracture during cortisone treatment
There is effective protection against hip fracture for the many elderly people whose skeleton is declining in strength, as a side effect of cortisone treatment. If patients receive the osteoporosis medication alendronate, it reduces the risk of hip fracture by 65 percent, as a study published in The Journal of the American Medical Association (JAMA) reveals. (2017-07-12)

Tumor-targeting drug shows potential for treating bone cancer patients
The treatment of osteosarcoma, the most common tumor of bone, is challenging. A study led by The University of Texas MD Anderson Cancer Center found a drug known as bone metastasis-targeting peptidomimetic (BMTP-11) has potential as a new therapeutic strategy for this devastating illness. (2017-07-12)

WHO decision to downgrade Tamiflu 'comes far too late' argues expert
The World Health Organization's decision to downgrade the influenza drug Tamiflu on its essential medicines list is better late than never, but still comes far too late, argues an expert in The BMJ today. (2017-07-12)

Use of osteoporosis drug with anti-inflammatory medication linked to lower risk of hip fracture
Among older patients using medium to high doses of the anti-inflammatory steroid prednisolone, treatment with the osteoporosis drug alendronate was associated with a significantly lower risk of hip fracture, according to a study published by JAMA. (2017-07-11)

Rural physicians report significant barriers in treating opioid use disorder
This item features an article published in the July/August 2017 Annals of Family Medicine. (2017-07-10)

Teaching old drugs new tricks in the fight against infectious diseases
A new article looks at how currently available drugs for various conditions might be repurposed alone or in combination with other drugs to treat infectious diseases. (2017-07-07)

Tenofovir alafenamide in chronic hepatitis B: Added benefit not proven, data incomplete
No added benefit can be derived from the incompletely submitted data for adolescents or adults. The postulated better tolerability is not proven. (2017-07-05)

As competition goes down, generic drug prices rise, study finds
If the cost of your generic prescription drug has risen, it may be due to a lack of competition among drug manufacturers, according to a University of Florida College of Pharmacy study. (2017-07-05)

The role of electrochemotherapy in radiosensitization of tumor cells
Using targeted drug delivery along with selective sensitizing tumors to therapeutic agents are the pioneering scientific efforts in cancer treatment. This study systematically reviewed the literature on the radiosensitizing effects of electrochemotherapy (ECT) to ionization radiation in different tumors and clinical perspectives are discussed. (2017-07-04)

Inhibition of tau protein aggregation by rhodanine-based compounds
Several peptide-polymer conjugates were synthesized to enhance the uptake of compounds into cells and thus to improve their biomedical application. The aim of this study was to test whether the peptide-inhibitor complexes still retain their inhibitory activity on Tau aggregation. (2017-06-30)

Treatment benefits patients with thalassaemia and HCV
Many individuals with the blood disorder thalassaemia also carry the hepatitis C virus (HCV) due to contaminated transfusions before 1990. (2017-06-29)

Mitochondria-targeted antioxidant SkQ1 helps to treat diabetic wounds
Members of the Faculty of Biology and A.N. Belozersky Institute of Physico-Chemical Biology, a unit of the Lomonosov Moscow State University, have tested on a mouse model a mitochondria-targeted antioxidant, helping to treat diabetic wounds. (2017-06-29)

Elephantiasis on the decline in Cameroon
Lymphatic filariasis -- a parasitic infection commonly known as elephantiasis -- is among the 10 neglected tropical diseases that the World Health Organization (WHO) is aiming to eliminate by 2020. In Cameroon, large-scale annual mass drug administration efforts are successfully curbing rates of LF, researchers now report in PLOS Neglected Tropical Diseases. (2017-06-29)

Researchers examine brain region that affects drug use habits
University of Iowa researchers have identified a brain region involved in cocaine addiction. The findings could lead to targeted drugs or improved behavioral treatments for substance addiction, including opioid dependency. Findings published in the Journal of Neuroscience. (2017-06-27)

Fatality rates are high within 2 years of drug-induced liver injury
Most patients suffering liver toxicity due to medications or herbal or dietary supplements recover from the acute liver injury without long-term problems, but some do not survive the injury or they require liver transplantation. (2017-06-26)

Targeted drug shows promise in rare advanced kidney cancer
Some patients with a form of advanced kidney cancer benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by Dana-Farber Cancer Institute scientists. (2017-06-23)

An integrated perspective on diabetic, alcoholic, and drug-induced neuropathy
Neuropathic pain (NeuP) is a persistent, debilitating form of chronic pain that results from damaged nerves. It has multiple underlying etiologies, including diabetes, alcohol and chemotherapy, and is thought to affect 7-10% of the global population. (2017-06-22)

Finding the perfect match: A new approach to battle drug-resistant bacteria
Antibiotics were the wonder drug of the 20th century, but persistent use and over-prescription have opened the door that has allowed bacteria to evolve resistance. According to the CDC, more than two million people in the US develop bacterial infections that are resistant to multiple antibiotics every year. Researchers at University of Utah Health developed a rapid screening method to pair existing FDA-approved drugs to combat multi-drug resistant bacterial infections. (2017-06-20)

Implant infections could be banished thanks to scaffold breakthrough
Researchers in Ireland have taken a major step forward in the battle against medical implant infections. They developed a new type of implant scaffold to provide localised drug treatment and prevent infection, which has already proven effective against two types of major problem bacteria. (2017-06-19)

Sex-specific cardiovascular drug dosages needed to reduce adverse reactions in women
Sex-specific cardiovascular drug dosages are needed to reduce adverse reactions in women, according to a position paper from the European Society of Cardiology published today in the June issue of European Heart Journal - Cardiovascular Pharmacotherapy. (2017-06-15)

Inhibitor drug improves overall survival in older radioiodine resistant thyroid cancer
The drug lenvatinib can significantly improve overall survival rates in a group of thyroid cancer patients whose disease is resistant to standard radioiodine treatment, according to new research from the Perelman School of Medicine at the University of Pennsylvania. The study, published today in the Journal of Clinical Oncology, is the first to show lenvatinib has a definitive impact on overall survival (OS). Researchers found OS improves in patients older than 65 years of age and that the drug is well-tolerated. (2017-06-15)

Cancer researchers look at resistance to targeted therapy in mantle cell lymphoma
A team of cancer researchers at the George Washington University Cancer Center published research looking at the underlying mechanisms of resistance to the drug, Ibrutinib, which is used to treat patients with mantle cell lymphoma. (2017-06-14)

Major new appetite regulator successfully manipulated in mice
A study from Imperial has found new a link between certain brain receptors and obesity, giving a possible new drug target for appetite regulation. (2017-06-13)

Previously unpublished trial data explain effects and side effects of key MS drug
Through a Freedom of Information request to the European Medicines Agency, researchers from Queen Mary University of London (QMUL) gained access to the phase III trial datasets of Alemtuzumab, and publish new insights (JAMA Neurology) into the drastic response of the immune system in patients with MS. (2017-06-12)

Drug developed for arthritis could be first to stop heart valve calcification
About a quarter of Americans suffer hardening of the valves by age 65, and the only treatment has been surgical replacement. (2017-06-12)

New cancer drug makes commonly prescribed chemo drug more effective when given together
Researchers have found a way to increase the effectiveness of a widely used cancer drug while decreasing the risk of heart-damaging side effects, according to a new study by researchers from The University of Texas Medical Branch at Galveston and Texas Tech University Health Sciences Center. The findings are currently available in the Journal Scientific Reports Nature publishing group. (2017-06-12)

Major study heralds new era in treatment of type 2 diabetes
A drug that lowers blood sugar levels for people with type 2 diabetes has also been revealed to significantly reduce the risk of both cardiovascular and kidney disease. The study by The George Institute for Global Health has major implications for the treatment of type 2 diabetes which affects around 450 million people worldwide. (2017-06-12)

Drug combination benefits patients with tophaceous gout
The drug lesinurad in combination with febuxostat was better at lowering blood levels of urate than febuxostat alone in a phase III clinical trial of 324 patients with tophaceous gout. (2017-06-09)

Heroin's use rising, costing society more than $51 billion
Heroin use in the United States was estimated to cost society more than $51 billion in 2015, according to new research at the University of Illinois at Chicago. (2017-06-08)

New cellular imaging paves way for cancer treatment
Researchers at the Universities of York and Leiden have pioneered a technique which uses florescent imaging to track the actions of key enzymes in cancer, genetic disorders and kidney disease. (2017-06-08)

Imaging technique could be game changer for pharma
In drug development, the body can be something of a black box. We take medicine and observe the overall effects, but what happens inside the body largely remains a mystery. To help clear up this picture, researchers are turning to imaging techniques in tissue and animal testing. The step has gained ground in the drug industry, according to a story in Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society. (2017-06-07)

Mutations unveiled that predispose lung cancers to refractory histologic transformation
Cancer pedigree analysis reveals the mutations in RB1 and TP53 genes play a key role in treatment-resistant, cancer cell-type transformation during EGFR inhibitor therapy for lung cancers. (2017-06-07)

Anti-nausea drug could help treat sleep apnea
An old pharmaceutical product may be a new treatment for obstructive sleep apnea, according to new research presented today by University of Illinois at Chicago and Northwestern University scientists at the SLEEP 2017 annual meeting in Boston. (2017-06-06)

Standard dosage for one lung cancer treatment may be too high
A new study published in the Journal of the National Cancer Institute indicates that the customary pembrolizumab dose for treatment of metastatic non-small cell lung cancer may be higher than is needed for effective treatment. (2017-06-06)

Adding vemurafenib doubles progression-free survival in BRAF metastatic colorectal cancer
Clinical trial results presented in an oral abstract session 3:00pm Monday, June 5 at the American Society for Clinical Oncology (ASCO) Annual Meeting 2017 shows promising results for the addition of vemurafenib (anti-BRAF) to treatment with cetuximab and irinotecan (anti-EGFR) in patients with metastatic colorectal cancer that have a BRAF V600E mutation. (2017-06-05)

Targeted therapies show initial effectiveness in subset of papillary thyroid cancer
Two immunotherapy drugs currently approved by the US Food and Drug Administration (FDA) for the treatment of melanoma also show promise for treating a rare but aggressive form of papillary thyroid cancer, according to new research led by The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. (2017-06-05)

Injectable solution may provide weeks of glucose control
Biomedical engineers at Duke University have created a biopolymer that can provide weeks of glucose control with a single injection. The new tool has the potential to replace daily or weekly insulin shots with bi-weekly or once-a-month treatments of glucagon-like peptide-1 (GLP1) for type 2 diabetes. (2017-06-05)

Page 25 of 25 | 1000 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.